Eton Pharmaceuticals Reports Unregistered Equity Sales
Ticker: ETON · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1710340
Sentiment: neutral
Topics: equity-sale, unregistered-securities, capital-raise
Related Tickers: ETRN
TL;DR
ETRN sold unregistered equity, could mean dilution.
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on April 18, 2024, reporting unregistered sales of equity securities. The filing details transactions that occurred on April 15, 2024, related to the company's equity.
Why It Matters
This filing indicates potential dilution for existing shareholders and provides insight into the company's capital-raising activities.
Risk Assessment
Risk Level: medium — Unregistered sales of equity can lead to dilution and may signal the company is raising capital under less transparent terms.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- 20240418 (date) — Filing Date
- 20240415 (date) — Date of Earliest Event Reported
FAQ
What type of equity securities were sold?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the exact type of securities in the provided text.
Were these sales registered with the SEC?
No, the filing explicitly states 'Unregistered Sales of Equity Securities'.
What was the date of the reported transactions?
The earliest event reported, which includes the sales, occurred on April 15, 2024.
What is Eton Pharmaceuticals' primary business?
Eton Pharmaceuticals, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
Where is Eton Pharmaceuticals headquartered?
The company's principal executive offices are located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-04-18 16:22:57
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
- $3.50 — 00 shares of common stock at a price of $3.50 per share or total proceeds of $4,506,2
- $4,506,250 — of $3.50 per share or total proceeds of $4,506,250, (ii) agreements to issue pre-funded wa
- $8,618,750 — s of common stock for total proceeds of $8,618,750 or $3.50 per share. The Company also en
- $21.9 million — expand its existing credit facility by $21.9 million to $27.0 million and in connection ther
- $27.0 million — ing credit facility by $21.9 million to $27.0 million and in connection therewith agreed to i
- $3.66 — 76 shares of common stock at a price of $3.66 per share (the above items, collectivel
Filing Documents
- eton20240412_8k.htm (8-K) — 25KB
- 0001437749-24-012443.txt ( ) — 153KB
- eton-20240415.xsd (EX-101.SCH) — 3KB
- eton-20240415_def.xml (EX-101.DEF) — 11KB
- eton-20240415_lab.xml (EX-101.LAB) — 15KB
- eton-20240415_pre.xml (EX-101.PRE) — 11KB
- eton20240412_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 18, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 3